Efficacy of Acupuncture for Postoperative Urinary Retention Following Radical Hysterectomy for Cervical Cancer (APOUR)
16. juli 2026 oppdatert av: Obstetrics & Gynecology Hospital of Fudan University
Evaluation of the Efficacy of Acupuncture Combined With Intermittent Catheterization for Postoperative Urinary Retention Due to Neurogenic Bladder Following Radical Hysterectomy for Cervical Cancer
The goal of this clinical trial is to learn if acupuncture works to treat postoperative urinary retention in patients who have undergone radical hysterectomy for cervical cancer. The main question it aims to answer is:
Does acupuncture lower the volume of post-void residual in participants who need to use intermittent catheterization to assist with voiding after radical hysterectomy for cervical cancer?
Researchers will compare acupuncture to sham acupuncture (non-penetrating needles: using placebo needles with a blunt tip that gives the sensation of skin penetration without actually piercing the skin) to see if acupuncture works to treat postoperative urinary retention.
Participants will:
- Receive acupuncture or sham acupuncture or tamsulosin for 2 weeks.
- Visit the clinic before and after treatment for checkups and tests.
- Keep a voiding diary and record the volume of post-void residual and the number of times they use intermittent catheterization.
Studieoversikt
Status
Har ikke rekruttert ennå
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
324
Fase
- Ikke aktuelt
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Patients with a pathologically confirmed diagnosis of cervical cancer who have undergone radical hysterectomy for cervical cancer.
- Patients who developed urinary retention after catheter removal during routine postoperative follow-up (2-4 weeks after surgery), with post-void residual urine volume measured by ultrasound exceeding 100 ml on two consecutive occasions.
- Aged ≥18 years.
- Patients who are informed and voluntarily sign the informed consent form.
- Patients with a Karnofsky Performance Status (KPS) score ≥70 .
Exclusion Criteria:
- Patients with a clear preoperative diagnosis of urinary retention or voiding dysfunction.
- Patients with urinary retention caused by conditions other than radical surgery for cervical cancer, such as spinal cord injury or other diseases.
- Patients with severe heart, lung, or kidney failure, or those with severe medical comorbidities.
- Patients with a severe bleeding tendency due to any cause.
- Patients with severe consciousness disorders or psychiatric/psychological conditions that preclude cooperation with treatment.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Akupunktur
|
Participants receive acupuncture treatment in addition to intermittent catheterization and an α-blocker (e.g., tamsulosin).
Acupoints selected: Zhongji (CV3), Yinlingquan (SP9), Sanyinjiao (SP6), Ciliao (BL32), Zhongliao (BL33), Pangguangshu (BL28), Zhibian (BL54).
Treatment lasts for 2 weeks.
|
|
Placebo komparator: Sham akupunktur
|
Participants receive sham acupuncture treatment in addition to intermittent catheterization and an α-blocker (e.g., tamsulosin).
The same acupoints as in the acupuncture group are selected.
Sham acupuncture method: using a placebo needle device with a blunt tip that gives the sensation of skin penetration without actually piercing the skin.
Treatment lasts for 2 weeks.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Post-void residual urine volume (PVR)
Tidsramme: pre-intervention，immediately after the intervention
|
Measured via B-mode ultrasound after spontaneous voiding following catheter removal and ingestion of approximately 1000 ml of water.
|
pre-intervention，immediately after the intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Voiding diary
Tidsramme: pre-intervention，immediately after the intervention
|
Standardized recording of urinary frequency, volume, and symptom patterns over a defined period.
|
pre-intervention，immediately after the intervention
|
|
Maximum urinary flow rate (Qmax)
Tidsramme: pre-intervention，immediately after the intervention
|
Peak flow rate during voiding, obtained via urodynamic assessment.
|
pre-intervention，immediately after the intervention
|
|
First desire to void (FDV)
Tidsramme: pre-intervention，immediately after the intervention
|
Volume of urine in the bladder at the initial sensation of needing to urinate, obtained via urodynamic assessment.
|
pre-intervention，immediately after the intervention
|
|
International Consultation on Incontinence Questionnaire - Female Lower Urinary Tract Symptoms Long Form
Tidsramme: pre-intervention，immediately after the intervention
|
International Consultation on Incontinence Questionnaire for Female Lower Urinary Tract Symptoms (long form), used to quantify symptom burden and quality of life impact.
The minimum value of the questionnaire is 0 and the maximum value is 69.
Higher scores mean a worse outcome.
|
pre-intervention，immediately after the intervention
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. juli 2026
Primær fullføring (Antatt)
30. juni 2028
Studiet fullført (Antatt)
31. desember 2028
Datoer for studieregistrering
Først innsendt
10. juni 2026
Først innsendt som oppfylte QC-kriteriene
16. juli 2026
Først lagt ut (Faktiske)
17. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
17. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
16. juli 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- FUOBGY-2025-200
- 2025YFC3508302 (Annet stipend/finansieringsnummer: National Key Research and Development Program of China)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .